Companies › Taisho Pharmaceutical
1 active drug program in 5 registered trials: 4 Phase 3, 1 Phase 1; Gastroenterology, Genitourinary; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TS-172 Phosphate binder | – | Phase 3 | Hyperphosphatemia Patients on Hemodialysis; Hyperphosphatemia Patients on Peritoneal Dialysis; Patients With Mild or Moderate Hepatic Impairment | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07231029 | TS-172 | Phase 1 | Patients With Mild or Moderate Hepatic Impairment | Gastroenterology | Oct 2026 |
| NCT07548840 | TS-172 | Phase 3 | Hyperphosphatemia Patients on Hemodialysis | Genitourinary | Nov 2026 |
| NCT07285291 | TS-172 | Phase 3 | Hyperphosphatemia Patients on Hemodialysis | Genitourinary | Dec 2026 |
| NCT07548853 | TS-172 | Phase 3 | Hyperphosphatemia Patients on Peritoneal Dialysis | Genitourinary | May 2027 |
| NCT07285304 | TS-172 | Phase 3 | Hyperphosphatemia Patients on Hemodialysis | Genitourinary | Jul 2027 |
No annotated target.
–
Elgan Pharma Cinclus Pharma Holding Vantive Health Norgine Fertility Center of Las Vegas
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.